Human Immunodeficiency Virus Infection: Merck Manual Home Edition Drugs For HIV Infection Type Drug Side Effects Non-nucleoside reverse transcriptase inhibitors - Delavirdine Rash, headaches - Efavirenz Dizziness, sleepiness, nightmares, confusion, agitation, forgetfulness, euphoria, rash - Nevirapine Rash (occasionally severe or life threatening), liver dysfunction Nucleoside and nucleotide reverse transcriptase inhibitors - - All may cause...
THE MERCK MANUAL, Sec. 13, Ch. 154, Antiviral Drugs This Publication Is Searchable The Merck Manual of Diagnosis and Therapy--- Section 13.Zidovudine Zidovudine (ZDV, AZT) is a thymidine analog that inhibits the viral reverse transcriptase as a chain terminator.
Human Immunodeficiency Virus Infection: Merck Manual Home Edition Drugs For HIV Infection Type Drug Side Effects Non-nucleoside reverse transcriptase inhibitors - Delavirdine Rash, headaches - Efavirenz Dizziness, sleepiness, nightmares, confusion, agitation, forgetfulness, euphoria, rash - Nevirapine Rash (occasionally severe or life threatening), liver dysfunction Nucleoside and nucleotide reverse transcriptase inhibitors - - All may cause...
A to Z List - Medication Information A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z - A Abacavir Abacavir, lamivudine, zidovudine Acyclovir Alendronate Allopurinol Amifostine Amitriptyline Amlodipine Amoxicillin Amoxicillin / clavulanic acid Amphotericin B Ampicillin Amprenavir Anti-thymocyte globulin Asparaginase Atenolol Atovaquone Atracurium Azithromycin top - -...
author: St. Jude Children's Research Hospital
Patient Information Drug Information Sheet for Patients Antiretroviral Drug Classes Nucleoside Analogue Reverse Transcriptase Inhibitors 2,3-Dideoxycytidine (ddC, Hivid®) Abacavir (1592U89, Ziagen®) Abacavir (Ziagen) Hypersensitivity Reaction -- Didanosine(DDI, VIDEX® chew tabs, VIDEX® EC) - Lamivudine (3TC, Epivir®) (Combivir® - with AZT) Stavudine (d4T, Zerit®)...
http://www.fda.gov/cder/orange/appendix_a.txt 4, ACETAMINOPHEN TYLENOL W/ CODEINE, ACETAMINOPHEN TYLENOL, ACETAMINOPHEN (OTC) TYLOX, ACETAMINOPHEN TYLOX-325, ACETAMINOPHEN TYMTRAN, CERULETIDE DIETHYLAMINE TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE TZ-3, TIOCONAZOLE (OTC) ** U ** U-CORT, HYDROCORTISONE ACETATE U-GENCIN, GENTAMICIN SULFATE UCEPHAN, SODIUM BENZOATE ULO, CHLOPHEDIANOL HYDROCHLORIDE ULTANE, SEVOFLURANE ULTIVA,...
THE MERCK MANUAL, Sec. 13, Ch. 154, Antiviral Drugs This Publication Is Searchable The Merck Manual of Diagnosis and Therapy--- Section 13Zidovudine Zidovudine (ZDV, AZT) is a thymidine analog that inhibits the viral reverse transcriptase as a chain terminator
HIV GenoSure Report--11-25-03.ai ©2003 Laboratory Corporation of America ® Holdings All Rights Reserved L890- 1103- 5 6170574201 1912 Alexander Drive Research Triangle Park NC, 27709 (800) 533- 0567 GENOTYPING REPORT Patient Information Routing Information Account Information / Age: Months Years Birth Date: Sex: SSN: Patient ID: SAMPLE, TEST Name / Initials: Visit: 10/ 31/ 2003 Reported: 10/ 23/ 2003...
author: harrelc
Drug Index L-ascorbic acid ; AA; Calcium Ascorbate L-Chicoric acid ; Dicaffeic acid ester L-D4A ; L-2',3'-Didehydro-2',3'-dideoxyadenosine L-D4FC ; L-2',3'-Didehydro-2',3'-dideoxy-5-fluorocytidine L-D4G ; L-2',3'-Didehydro-2',3'-deoxyguanosine L-D4I ; L-2',3'-Didehydro-2',3'-dideoxyinosine L-FddC ; b-L-5F-ddC Lamivudine ;Epivir®; 3TC; Approved Lamivudine & Zidovudine ;...
Drug Index L-ascorbic acid ; AA; Calcium Ascorbate L-Chicoric acid ; Dicaffeic acid ester L-D4A ; L-2',3'-Didehydro-2',3'-dideoxyadenosine L-D4FC ; L-2',3'-Didehydro-2',3'-dideoxy-5-fluorocytidine L-D4G ; L-2',3'-Didehydro-2',3'-deoxyguanosine L-D4I ; L-2',3'-Didehydro-2',3'-dideoxyinosine L-FddC ; b-L-5F-ddC Lamivudine ;Epivir®; 3TC; Approved Lamivudine & Zidovudine ;...
NDAs Approved under Subpart H NDAs Approved under Subpart H NDA # Trade Name Generic -Name Clock Date Approval Date AP Time Approval Basis Indication - - - - - - - - 20199 Hivid Zalcitabine 31-Oct-91 19-Jun-92 7.6 S Combination therapy with zidovudine in advanced HIV infection - - - - - - - - 50698 Biaxin Clarithromycin- 2-Nov-92 23-Dec-93 13.7 S Treatment of disseminated mycobacterial infections due to...
author: Darlene Norris
Lexiva Tablets 1 PRESCRIBING INFORMATION LEXIVA™ (fosamprenavir calcium) Tablets PATIENT INFORMATION INCLUDED DESCRIPTION LEXIVA (fosamprenavir calcium) is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
author: glaxosmithkline, 0173
subject: fosamprenavir calcium
duplicates:http://www.aurorabio.com/pdfs/Lexiva102003label.pdf
http://www.adis.com/files/newsletters/AIT/AICOV58.PDF falciparum interactions 14 Azithromycin monotherapy in CAP 6 Bloodstream infections generate high costs 13 CAP care improved with multicentre intervention 12 Caspofungin + amphotericin B for paediatric aspergillosis 7 Efavirenz: substitution for PIs in HAART 8 Enfuvirtide: cost and QOL effect in HIV infections 3 Hepatitis A vaccine: booster not necessary 5 HIV infections: new agents...
V:\DAVDP\CSO\ONeill\NDA\20778-79 & 21503\Supp\SUP 020&041&002\SL\ R020&041&002approvalletter.doc page 5
author: Jeff ONeill
CME HIV Resistance Testing Article These residues include (but are not Table 1 DRUGS APPROVED FOR HIV THERAPY Nucleoside Reverse Transcriptase Inhibitors Generic name (Trade Name) Target Manufacturer AZT (Zidovudine) RT GlaxoSmithKline DDI (Didanosine) RT Bristol- Myers Squibb DdC (Zalcitabine) RT Hoffmann- La Roche d4T (Stavudine) RT Bristol- Myers Squibb 3TC (Lamivudine) RT GlaxoSmithKline Abacavir RT...
CME HIV Resistance Testing Article page 4
http://www.fda.gov/cder/foi/label/2001/20779s32lbl.pdf Table 1: Drug Interactions Effect of Nelfinavir on Coadministered Drug Plasma AUC and Cmax Coadministered Drug Coadministered Drug Nelfinavir Dose N AUC (95% CI) Cmax (95% CI) Lamivudine 150 mg Single Dose 750 mg q8h x 7- 10 days 11 10% (1- 20%) 31% (5- 62%) Stavudine 30- 40 mg bid x 56 days 750 mg tid x 56 days 8 Zidovudine 200 mg Single Dose 750 mg q8h x 7- 10 days 11...
http://www.fda.gov/cder/foi/label/2001/20779s32lbl.pdf page 5
Virco Drugs and Resistance - Despite the availability of up to 16 drugs to fight HIV infections, many treatments fail in the long run. Resistance to these drugs is one of the leading causes of treatment failure. ...
Virco - Home About News Virco Services Healthcare Professionals PLWHA Pharma Services HIV Information FAQs Contact ---General--- ---TDM--- - ---Global HIV epidemic--- ---HIV Dynamics--- ---HIV Variation--- ---Drugs ...
Efficacy Supplements Approved in Calendar Year 2002 (SE1-SE7 AND SE8s ----------- This list is updated quarterly.- Updated through 12/31/02 -------------------- Top of Page ---------- EFFICACY SUPPLEMENTS APPROVED IN CALENDAR YEAR 2002 (SE8)* Top of Page GENERIC NAME APPLICANT NDA NUMBER SUPP TYPE SUPP NUMBER RECEIPT DATE APPROVAL DATE PRIORITY REVIEW TOTAL APPROVAL TIME (MONTHS) ABACAVIR SULFATE, LAMIVUDINE, AND ZIDOVUDINE GLAXOSMITHKLINE...
author: Darlene Norris
Guidance for Industry - Premarket Notifications [510(k)s] for In Vitro HIV Drug Resistance Genotype Assays: Special Controls Drug Degree Associated Mutations - Zidovudine - Primary K70R; T215Y, or F Secondary M41L; D67N; L210W; K219Q Stavudine Primary V75T - Didanosine - Primary L74V Secondary K65R; M184V, or I Zalcitabine Secondary K65R; T69D; L74V; M184V, or I Lamivudine Primary E44D; V118I; M184V, or I - Abacavir - Primary K65R; L74V; M184V Secondary M41L; D67N; K70R; Y115F; L210W; T215Y, or...
author: FDA / CBER
ACL-Heilek-Snyder-HIV-Oct02-l/o For instance, there are now computerized analyses of current genotype databases that can answer questions regarding the frequency of specific combinations of mutations occurring in differ The benefits of HIV resistance testing in optimizing drug discovery BY GABRIELLE HEILEK- SNYDER AND PAMELA BEAN Table 1 FDA- approved drugs for the treatment of HIV/ AIDS* Nucleoside analog reverse...
author: Rachel Domack
ACL-Heilek-Snyder-HIV-Oct02-l/o page 1
author: Rachel Domack
ranbaxy - - - - -- - You are here :- Home - News Room - October 2002 RANBAXY'S Q3 NET PROFIT (PAT) UP BY 79% US SALES SURPASS US$ 200 MN: JANUARY – SEPTEMBER 2002 October 16, 2002, New Jersey, USA The Board of ...
